CMS(00867) self-developed innovative drug cardiac myosin inhibitor CMS-D003 obtained the drug clinical trial approval notice.

CMS (00867) announced that the innovative drug CMS-D003 capsule, which was independently developed by the group, received the drug clinical trial approval notification issued by the National Medical Products Administration (NMPA) of China on March 11, 2025, and received the drug clinical trial approval notification on March 12. NMPA has agreed for the group to conduct clinical trials in adult subjects with Chinese health and obstructive hypertrophic cardiomyopathy (oHCM) to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic characteristics of CMS-D003.